NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PALI
Palisade Bio, Inc.
There isn't enough reported data to score PALI yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PALI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Weak | |
| Unavailable |
PALI's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PALI PE Valuation
PALI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PALI Forward outlook
There aren't enough analyst estimates for PALI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus PALI down 116%.
PALI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$13.83 | +$71.28 |
| Q2 2024 | -$18.86 | +$118.90 |
| Q1 2024 | -$23.49 | +$196.32 |
| Q4 2023 | -$27.00 | +$328.85 |
| Q3 2023 | -$85.11 | -116% |
| Q2 2023 | -$137.76 | -115% |
| Q1 2023 | -$219.81 | +$1,874.33 |
| Q4 2022 | -$355.85 | +$2,186.65 |
PALI lost $13.83 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PALI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PALI on profitability, with a higher operating margin.
PALI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $2.5K | 0% |
PALI's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2340% | N/A |
| Q1 2023 | -1012% | N/A |
| Q4 2020 | -175764% | -90461 points |
| Q3 2020 | -93745% | N/A |
| Q2 2020 | -77894% | N/A |
| Q1 2020 | -33064% | N/A |
| Q4 2019 | -85303% | N/A |
PALI's operating margin was −2340% last quarter, up 75555 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PALI on cash generation, producing positive trailing cash flow while its opponent burns cash.
PALI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.8M | -$8.2M |
| Q2 2026 | -$7.6M | -$5.8M |
| Q1 2026 | -$3.9M | -$1.6M |
| Q4 2025 | -$3.1M | -$763K |
| Q3 2025 | -$3.6M | -$420K |
| Q1 2025 | -$2.3M | +$847K |
| Q4 2024 | -$2.4M | +$365K |
| Q3 2024 | -$3.1M | -$471K |
PALI has burned cash in almost every quarter: −$26M over the past year, against −$10M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PALI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PALI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +646K shares |
| 1 year | +4320% | +207M shares |
| 3 years | +73597% | +212M shares |
| 5 years | +6879452% | +212M shares |
PALI has 212M diluted shares, up 4320% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PALI Net Leverage
PALI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PALI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.9 | Oversold |
PALI's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PALI PE vs Healthcare Sector
PALI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over PALI on trend strength, trading above more of its moving averages.
PALI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 14% below |
| 20 week MA | $1.73 | 34% below |
| 50 week MA | $1.82 | 37% below |
| 100 week MA | $1.47 | 22% below |
| 200 week MA | $7.14 | 84% below |
PALI is in a downtrend: it's below all five of its weekly moving averages, and 84% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PALI on returns for 2026, with the stronger performance.
PALI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4,103.9 | $4,025.6 | -1.9% |
| 2021 | $4,025.6 | $1,252.5 | -69% |
| 2022 | $1,252.5 | $28.7 | -98% |
| 2023 | $28.7 | $8.85 | -69% |
| 2024 | $8.85 | $1.67 | -81% |
| 2025 | $1.67 | $2.15 | +29% |
| 2026 YTD | $2.15 | $1.14 | -47% |
PALI has finished lower in five of the last six years. It's down 47% so far in 2026.